Media Relations News Releases Year: - Any -20202019201820172016 Items per page 102550 May 11, 2018 Summary ToggleNovartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis May 1, 2018 Summary ToggleKymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma Apr 17, 2018 Summary ToggleNovartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials Apr 17, 2018 Summary ToggleNovartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures Mar 22, 2018 Summary ToggleKymriah™ (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval for certain adults with r/r DLBCL Feb 16, 2018 Summary ToggleNovartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis Feb 16, 2018 Summary ToggleNovartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis Jan 31, 2018 Summary ToggleNovartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah™ in children, young adults with r/r ALL Dec 10, 2017 Summary TogglePrimary analysis results from Novartis pivotal JULIET trial show Kymriah™ (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer Nov 30, 2017 Summary ToggleNovartis’ Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients Pagination First page First Previous page Previous … Page 4 Current page 5 Page 6 Page 7 … Next page Next Last page Last
